VItamin K In PEritonial DIAlysis

Vascular calcification (VC) is an active process, resulting from the disturbance of balance between inhibitors and promoters of calcification, in favor of the latter. Matrix Gla Protein, a powerful inhibitor of VC, needs vitamin K to become active. In vitamin K depletion, plasma levels of the inacti...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 17; no. 8; p. e0273102
Main Authors Roumeliotis, Stefanos, Roumeliotis, Athanasios, Georgianos, Panagiotis I, Thodis, Elias, Schurgers, Leon J, Maresz, Katarzyna, Eleftheriadis, Theodoros, Dounousi, Evangelia, Tripepi, Giovanni, Mallamaci, Francesca, Liakopoulos, Vassilios
Format Journal Article
LanguageEnglish
Published Public Library of Science 17.08.2022
Subjects
Care and treatment
Chronic kidney failure
Clinical trials
Diagnosis
Evaluation
Health aspects
Vitamin K
France
Online AccessGet full text

Cover

More Information
Summary:Vascular calcification (VC) is an active process, resulting from the disturbance of balance between inhibitors and promoters of calcification, in favor of the latter. Matrix Gla Protein, a powerful inhibitor of VC, needs vitamin K to become active. In vitamin K depletion, plasma levels of the inactive form of MGP, dephosphorylated, uncarboxylated MGP (dp-ucMGP) are increased and associated with VC and cardiovascular (CV) outcomes. End Stage Renal Disease (ESRD) patients have increased circulating dp-ucMGP levels and accelerated VC. VItamin K In PEritoneal DIAlysis (VIKIPEDIA) is a prospective, randomized, open label, placebo-controlled trial, evaluating the effect of vitamin K2 supplementation on arterial stiffness and CV events in ESRD patients undergoing peritoneal dialysis (PD). Forty-four PD patients will be included in the study. At baseline, dp-ucMGP and pulse-wave velocity (PWV) will be assessed and then patients will be randomized (1:1 ratio) to vitamin K (1000 [mu]g MK-7/day) or placebo for 1.5 years. The primary endpoint of this trial is the change in PWV in the placebo group as compared to the treatment group. Secondary endpoints are the occurrence of CV events, mortality, changes in PD adequacy, change in 24-hour ambulatory blood pressure indexes and aortic systolic blood pressure and changes in calcium/phosphorus/parathormone metabolism. VIKIPEDIA is a new superiority randomized, open label, placebo-controlled trial aiming to determine the effect of vitamin K2 supplementation on VC, CV disease and calcium/phosphorus metabolism, in PD patients.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0273102